Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

NCT02273752 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Estrogen Receptor-positive Breast Cancer
Gastrinoma
Glucagonoma
HER2-negative Breast Cancer
Insulinoma
Mucositis
Oral Complications
Pancreatic Polypeptide Tumor
Progesterone Receptor-positive Breast Cancer
Recurrent Breast Cancer
Recurrent Islet Cell Carcinoma
Recurrent Renal Cell Cancer
Somatostatinoma
Stage III Renal Cell Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Stage IV Renal Cell Cancer

Interventions

DRUG: Everolimus

Sponsor

Emory University

Collaborators

[object Object]